Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

NCT00539253 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: gadobenate dimeglumine (MultiHance)

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]